Marshall Wace, LLP Eagle Pharmaceuticals, Inc. Transaction History
Marshall Wace, LLP
- $77.3 Billion
- Q3 2024
A detailed history of Marshall Wace, LLP transactions in Eagle Pharmaceuticals, Inc. stock. As of the latest transaction made, Marshall Wace, LLP holds 223,353 shares of EGRX stock, worth $129,544. This represents 0.0% of its overall portfolio holdings.
Number of Shares
223,353
Previous 195,475
14.26%
Holding current value
$129,544
Previous $1.09 Million
24.31%
% of portfolio
0.0%
Previous 0.0%
Shares
15 transactions
Others Institutions Holding EGRX
# of Institutions
70Shares Held
8.6MCall Options Held
1MPut Options Held
100-
Nantahala Capital Management, LLC New Canaan, CT2.36MShares$1.37 Million0.52% of portfolio
-
Aigh Capital Management LLC Baltimore, MD1.21MShares$702,6751.82% of portfolio
-
Citigroup Inc1MShares$580,2250.0% of portfolio
-
Vanguard Group Inc Valley Forge, PA580KShares$336,1140.0% of portfolio
-
Aqr Capital Management LLC Greenwich, CT375KShares$217,4950.0% of portfolio
About EAGLE PHARMACEUTICALS, INC.
- Ticker EGRX
- Exchange NASDAQ
- Sector Healthcare
- Industry Drug Manufacturers—Specialty & Generic
- Shares Outstandng 13,015,900
- Market Cap $7.55M
- Description
- Eagle Pharmaceuticals, Inc., a pharmaceutical company, focuses on developing and commercializing product candidates to treat diseases of the central nervous system or metabolic critical care, and oncology in the United States. The company offers Ryanodex for malignant hyperthermia; and Belrapzo and Bendeka for chronic lymphocytic leukemia and in...